Literature DB >> 34328537

Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture.

Hyejin Kim1, Sangyeop Lee2, EunJi Jo2, Suyeoun Kim2, Haeun Kim2, Eun-Geun Kim2,3, Sunghoon Kwon2,4, Soyoun Shin5,6.   

Abstract

The QuantaMatrix Microfluidic Agarose Channel (QMAC) system was used for rapid drug susceptibility testing (DST). Here, we performed DST using QMAC integrated with the mycobacteria growth indicator tube (MGIT) liquid culture employing a specially designed cross agarose channel for the tuberculosis chip. MGIT-, QMAC-, and Löwenstein-Jensen (LJ)-DSTs were performed using 13 drugs. The protocol for QMAC-DST was optimized using the inoculum obtained after the disaggregation of Mycobacterium tuberculosis clumps in MGIT culture. The completion times of QMAC-DST and MGIT-DST were analyzed, and the results of all three DSTs were compared. Discrepant results were analyzed using line probe assays and DNA sequencing. Nontuberculous mycobacteria were distinguished using the ρ-nitrobenzoic acid inhibition test. The overall agreement rate of QMAT-DST and LJ-DST was 97.0% and that of QMAT-DST and MGIT-DST was 86.3%. An average turnaround time for DST was 5.4 days, which was considerably less than the time required for MGIT-DST. The overall time required to obtain DST results using QMAC-DST integrated with MGIT culture was an average of 18.6 days: 13.2 days for culture and identification and 5.4 days for DST. Hence, QMAC-DST integrated with liquid culture can be used to perform DSTs with short turnaround times and effective detection. KEY POINTS: • QMAC system can simultaneously perform phenotypic DST with 13 anti-TB drugs and PNB. • An optimized DST protocol led to a marked decrease in clumping in MGIT culture. • QMAC system integrated with MGIT liquid culture system reduced the turnaround time.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  MGIT-DST; Mycobacterium tuberculosis; Phenotypic drug susceptibility testing; QMAC system

Year:  2021        PMID: 34328537     DOI: 10.1007/s00253-021-11446-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  37 in total

1.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis.

Authors:  Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona
Journal:  Lancet       Date:  2010-05-22       Impact factor: 79.321

2.  Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value.

Authors:  Maha R Farhat; Razvan Sultana; Oleg Iartchouk; Sam Bozeman; James Galagan; Peter Sisk; Christian Stolte; Hanna Nebenzahl-Guimaraes; Karen Jacobson; Alexander Sloutsky; Devinder Kaur; James Posey; Barry N Kreiswirth; Natalia Kurepina; Leen Rigouts; Elizabeth M Streicher; Tommie C Victor; Robin M Warren; Dick van Soolingen; Megan Murray
Journal:  Am J Respir Crit Care Med       Date:  2016-09-01       Impact factor: 21.405

3.  Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide.

Authors:  Pamela Chedore; Lina Bertucci; Joyce Wolfe; Meenu Sharma; Frances Jamieson
Journal:  J Clin Microbiol       Date:  2009-11-18       Impact factor: 5.948

4.  Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory.

Authors:  Sayera Banu; S M Mazidur Rahman; M Siddiqur Rahman Khan; Sara Sabrina Ferdous; Shahriar Ahmed; Jean Gratz; Suzanne Stroup; Suporn Pholwat; Scott K Heysell; Eric R Houpt
Journal:  J Clin Microbiol       Date:  2013-10-30       Impact factor: 5.948

5.  Rapid drug susceptibility test of Mycobacterium tuberculosis using microscopic time-lapse imaging in an agarose matrix.

Authors:  Jungil Choi; Jungheon Yoo; Ki-Jung Kim; Eun-Geun Kim; Kyung Ock Park; Hyejin Kim; Haeun Kim; Hyunju Jung; Taeyoung Kim; Myungjin Choi; Hee Chan Kim; Sungweon Ryoo; Yong-Gyun Jung; Sunghoon Kwon
Journal:  Appl Microbiol Biotechnol       Date:  2016-01-12       Impact factor: 4.813

Review 6.  Advances in the diagnosis of tuberculosis- Journey from smear microscopy to whole genome sequencing.

Authors:  K K Chopra; Zeeshan Sidiq; M Hanif; Kaushal Kumar Dwivedi
Journal:  Indian J Tuberc       Date:  2020-10-02

7.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

Authors:  G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

8.  Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Montserrat Garrigó; Lina Marcela Aragón; Fernando Alcaide; Sonia Borrell; Eugenia Cardeñosa; Juan José Galán; Julián Gonzalez-Martín; Nuria Martin-Casabona; Carmen Moreno; Margarita Salvado; Pere Coll
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

Review 9.  Defining the needs for next generation assays for tuberculosis.

Authors:  Claudia M Denkinger; Sandra V Kik; Daniela Maria Cirillo; Martina Casenghi; Thomas Shinnick; Karin Weyer; Chris Gilpin; Catharina C Boehme; Marco Schito; Michael Kimerling; Madhukar Pai
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

10.  Dramatic reduction of culture time of Mycobacterium tuberculosis.

Authors:  Ramzi Ghodbane; Didier Raoult; Michel Drancourt
Journal:  Sci Rep       Date:  2014-02-28       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.